Seminars in Nuclear Medicine
Volume 38, Issue 4 , Pages 227-239 , July 2008

Neuronuclear Assessment of Patients With Epilepsy

  • Karolien Goffin, MD

      Affiliations

    • Division of Nuclear Medicine, University Hospital Leuven, Leuven, Belgium.
    • ,
  • Stefanie Dedeurwaerdere, PhD

      Affiliations

    • Department of Medicine, University of Melbourne, Parkville, Australia.
    • ,
  • Koen Van Laere, MD, PhD, DSc

      Affiliations

    • Division of Nuclear Medicine, University Hospital Leuven, Leuven, Belgium.
    • ,
  • Wim Van Paesschen, MD, PhD

      Affiliations

    • Department of Neurology, University Hospital Leuven, Leuven, Belgium.
    • Corresponding Author InformationAddress reprint requests to Wim Van Paesschen, Department of Neurology, University Hospital Leuven Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium.

References 

  1. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: Definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46:470–472
  2. Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia. 1975;16:1–66
  3. Hart YM, Sander JW, Johnson AL, et al. National general practice study of epilepsy: Recurrence after a first seizure. Lancet. 1990;336:1271–1274
  4. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1981;22:489–501
  5. Li LM, Fish DR, Sisodiya SM, et al. High resolution magnetic resonance imaging in adults with partial or secondary generalised epilepsy attending a tertiary referral unit. J Neurol Neurosurg Psychiatry. 1995;59:384–387
  6. Rosenow F, Lüders H. Presurgical evaluation of epilepsy. Brain. 2001;124:1683–1700
  7. Elger CE, Helmstaedter C, Kurthen M. Chronic epilepsy and cognition. Lancet Neurol. 2004;3:663–672
  8. Wiebe S, Blume WT, Girvin JP, et al. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001;345:311–318
  9. Cohen-Gadol AA, Ozduman K, Bronen RA, et al. Long-term outcome after epilepsy surgery for focal cortical dysplasia. J Neurosurg. 2004;101:55–65
  10. Sharp PF, Smith FW, Gemmell HG, et al. Technetium-99m HM-PAO stereoisomers as potential agents for imaging regional cerebral blood flow: Human volunteer studies. J Nucl Med. 1986;27:171–177
  11. Vallabhajosula S, Zimmerman RE, Picard M, et al. Technetium-99m ECD: A new brain imaging agent: in vivo kinetics and biodistribution studies in normal human subjects. J Nucl Med. 1989;30:599–604
  12. O'Brien TJ, So EL, Mullan BP, et al. Subtraction ictal SPECT co-registered to MRI improves clinical usefulness of SPECT in localizing the surgical seizure focus. Neurology. 1998;50:445–454
  13. McNally KA, Paige AL, Varghese G, et al. Localizing value of ictal-interictal SPECT analyzed by SPM (ISAS). Epilepsia. 2005;46:1450–1464
  14. Maes F, Collignon A, Vandermeulen D, et al. Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging. 1997;16:187–198
  15. Dupont P, Van Paesschen W, Palmini A, et al. Ictal perfusion patterns associated with single MRI-visible focal dysplastic lesions: implications for the noninvasive delineation of the epileptogenic zone. Epilepsia. 2006;47:1550–1557
  16. Lee SK, Lee SY, Yun CH, et al. Ictal SPECT in neocortical epilepsies: Clinical usefulness and factors affecting the pattern of hyperperfusion. Neuroradiology. 2006;48:678–684
  17. Van Paesschen W, Dupont P, Sunaert S, et al. The use of SPECT and PET in routine clinical practice in epilepsy. Curr Opin Neurol. 2007;20:194–202
  18. Devous MD, Thisted RA, Morgan GF, et al. SPECT brain imaging in epilepsy: A meta-analysis. J Nucl Med. 1998;39:285–293
  19. Bartolini A. Regional arm-brain mean transit time in the diagnostic evaluation of patients with cerebral vascular disease. Stroke. 1981;12:241–245
  20. Shin WC, Hong SB, Tae WS, et al. Ictal hyperperfusion patterns according to the progression of temporal lobe seizures. Neurology. 2002;58:373–380
  21. Amorim BJ, Etchebehere EC, Camargo EE, et al. Statistical voxel-wise analysis of ictal SPECT reveals pattern of abnormal perfusion in patients with temporal lobe epilepsy. Arq Neuropsiquiatr. 2005;63:977–983
  22. Fukuda M, Masuda H, Honma J, et al. Ictal SPECT analyzed by three-dimensional stereotactic surface projection in frontal lobe epilepsy patients. Epilepsy Res. 2006;68:95–102
  23. Avery RA, Spencer SS, Spanaki MV, et al. Effect of injection time on postictal SPET perfusion changes in medically refractory epilepsy. Eur J Nucl Med. 1999;26:830–836
  24. Cherry SR. Multimodality in vivo imaging systems: Twice the power or double the trouble?. Annu Rev Biomed Eng. 2006;8:35–62
  25. Drzezga A, Arnold S, Minoshima S, et al. 18F-FDG PET studies in patients with extratemporal and temporal epilepsy: Evaluation of an observer-independent analysis. J Nucl Med. 1999;40:737–746
  26. Lin TW, de Aburto MA, Dahlbom M, et al. Predicting seizure-free status for temporal lobe epilepsy patients undergoing surgery: Prognostic value of quantifying maximal metabolic asymmetry extending over a specified proportion of the temporal lobe. J Nucl Med. 2007;48:776–782
  27. Gaillard WD, Zeffiro T, Fazilat S, et al. Effect of valproate on cerebral metabolism and blood flow: An 18F-2-deoxyglucose and 15O water positron emission tomography study. Epilepsia. 1996;37:515–521
  28. Theodore WH. Antiepileptic drugs and cerebral glucose metabolism. Epilepsia. 1988;29(suppl 2):S48–S55
  29. Hunter GJ, Hamberg LM, Alpert NM, et al. Simplified measurement of deoxyglucose utilization rate. J Nucl Med. 1996;37:950–955
  30. Quarantelli M, Berkouk K, Prinster A, et al. Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J Nucl Med. 2004;45:192–201
  31. Baete K, Nuyts J, Van Paesschen W, et al. Anatomical-based FDG-PET reconstruction for the detection of hypo-metabolic regions in epilepsy. IEEE Trans Med Imaging. 2004;23:510–519
  32. Baete K, Nuyts J, Van Laere K, et al. Evaluation of anatomy based reconstruction for partial volume correction in brain FDG-PET. Neuroimage. 2004;23:305–317
  33. Lee SK, Lee SY, Kim KK, et al. Surgical outcome and prognostic factors of cryptogenic neocortical epilepsy. Ann Neurol. 2005;58:525–532
  34. Breier JI, Mullani NA, Thomas AB, et al. Effects of duration of epilepsy on the uncoupling of metabolism and blood flow in complex partial seizures. Neurology. 1997;48:1047–1053
  35. Casse R, Rowe CC, Newton M, et al. Positron emission tomography and epilepsy. Mol Imaging Biol. 2002;4:338–351
  36. Park CK, Kim SK, Wang KC, et al. Surgical outcome and prognostic factors of pediatric epilepsy caused by cortical dysplasia. Childs Nerv Syst. 2006;22:586–592
  37. Ollenberger GP, Byrne AJ, Berlangieri SU, et al. Assessment of the role of FDG PET in the diagnosis and management of children with refractory epilepsy. Eur J Nucl Med Mol Imaging. 2005;32:1311–1316
  38. Yun CH, Lee SK, Lee SY, et al. Prognostic factors in neocortical epilepsy surgery: Multivariate analysis. Epilepsia. 2006;47:574–579
  39. Choi JY, Kim SJ, Hong SB, et al. Extratemporal hypometabolism on FDG PET in temporal lobe epilepsy as a predictor of seizure outcome after temporal lobectomy. Eur J Nucl Med Mol Imaging. 2003;30:581–587
  40. Henry TR, Babb TL, Engel J, et al. Hippocampal neuronal loss and regional hypometabolism in temporal lobe epilepsy. Ann Neurol. 1994;36:925–927
  41. Foldvary N, Lee N, Hanson MW, et al. Correlation of hippocampal neuronal density and FDG-PET in mesial temporal lobe epilepsy. Epilepsia. 1999;40:26–29
  42. Cornford EM, Gee MN, Swartz BE, et al. Dynamic [18F]fluorodeoxyglucose positron emission tomography and hypometabolic zones in seizures: Reduced capillary influx. Ann Neurol. 1998;43:801–808
  43. Nelissen N, Van Paesschen W, Baete K, et al. Correlations of interictal FDG-PET metabolism and ictal SPECT perfusion changes in human temporal lobe epilepsy with hippocampal sclerosis. Neuroimage. 2006;32:684–695
  44. McDonald CR, Swartz BE, Halgren E, et al. The relationship of regional frontal hypometabolism to executive function: a resting fluorodeoxyglucose PET study of patients with epilepsy and healthy controls. Epilepsy Behav. 2006;9:58–67
  45. Salzberg M, Taher T, Davie M, et al. Depression in temporal lobe epilepsy surgery patients: An FDG-PET study. Epilepsia. 2006;47:2125–2130
  46. Takaya S, Hanakawa T, Hashikawa K, et al. Prefrontal hypofunction in patients with intractable mesial temporal lobe epilepsy. Neurology. 2006;67:1674–1676
  47. Benedek K, Juhasz C, Chugani DC, et al. Longitudinal changes in cortical glucose hypometabolism in children with intractable epilepsy. J Child Neurol. 2006;21:26–31
  48. Joo EY, Hong SB, Han HJ, et al. Postoperative alteration of cerebral glucose metabolism in mesial temporal lobe epilepsy. Brain. 2005;128:1802–1810
  49. Van Paesschen W, Porke K, Fannes K, et al. Cognitive deficits during status epilepticus and time course of recovery: A case report. Epilepsia. 2007;48:1979–1983
  50. Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia. 2001;42(suppl 3):8–12
  51. Hammers A, Koepp MJ, Richardson MP, et al. Grey and white matter flumazenil binding in neocortical epilepsy with normal MRI (A PET study of 44 patients). Brain. 2003;126:1300–1318
  52. Padma MV, Simkins R, White P, et al. Clinical utility of 11C-flumazenil positron emission tomography in intractable temporal lobe epilepsy. Neurol India. 2004;52:457–462
  53. Koepp MJ, Richardson MP, Brooks DJ, et al. Cerebral benzodiazepine receptors in hippocampal sclerosis (An objective in vivo analysis). Brain. 1996;119:1677–1687
  54. Koepp MJ, Hand KS, Labbe C, et al. In vivo [11C]flumazenil-PET correlates with ex vivo [3H]flumazenil autoradiography in hippocampal sclerosis. Ann Neurol. 1998;43:618–626
  55. Hammers A, Koepp MJ, Brooks DJ, et al. Periventricular white matter flumazenil binding and postoperative outcome in hippocampal sclerosis. Epilepsia. 2005;46:944–948
  56. Hammers A, Panagoda P, Heckemann RA, et al. [(11)C]Flumazenil PET in temporal lobe epilepsy: Do we need an arterial input function or kinetic modeling?. J Cereb Blood Flow Metab. 2008;28:207–216
  57. Bouvard S, Costes N, Bonnefoi F, et al. Seizure-related short-term plasticity of benzodiazepine receptors in partial epilepsy: A [11C]flumazenil-PET study. Brain. 2005;128:1330–1343
  58. Chang YS, Jeong JM, Yoon YH, et al. Biological properties of 2′-[18F]fluoroflumazenil for central benzodiazepine receptor imaging. Nucl Med Biol. 2005;32:263–268
  59. Tortella FC, Long JB. Endogenous anticonvulsant substance in rat cerebrospinal fluid after a generalized seizure. Science. 1985;228:1106–1108
  60. Wagner JJ, Caudle RM, Neumaier JF, et al. Stimulation of endogenous opioid release displaces mu receptor binding in rat hippocampus. Neuroscience. 1990;37:45–53
  61. Frost JJ, Mayberg HS, Fisher RS, et al. Mu-opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy. Ann Neurol. 1988;23:231–237
  62. Mayberg HS, Sadzot B, Meltzer CC, et al. Quantification of mu and non-mu opiate receptors in temporal lobe epilepsy using positron emission tomography. Ann Neurol. 1991;30:3–11
  63. Madar I, Lesser RP, Krauss G, et al. Imaging of delta- and mu-opioid receptors in temporal lobe epilepsy by positron emission tomography. Ann Neurol. 1997;41:358–367
  64. Hammers A, Asselin MC, Hinz R, et al. Upregulation of opioid receptor binding following spontaneous epileptic seizures. Brain. 2007;130:1009–1016
  65. Pasini A, Tortorella A, Gale K. Anticonvulsant effect of intranigral fluoxetine. Brain Res. 1992;593:287–290
  66. Favale E, Rubino V, Mainardi P, et al. Anticonvulsant effect of fluoxetine in humans. Neurology. 1995;45:1926–1927
  67. Toczek MT, Carson RE, Lang L, et al. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology. 2003;60:749–756
  68. Theodore WH, Hasler G, Giovacchini G, et al. Reduced hippocampal 5HT1A PET receptor binding and depression in temporal lobe epilepsy. Epilepsia. 2007;48:1526–1530
  69. Giovacchini G, Toczek MT, Bonwetsch R, et al. 5-HT 1A receptors are reduced in temporal lobe epilepsy after partial-volume correction. J Nucl Med. 2005;46:1128–1135
  70. Ito S, Suhara T, Ito H, et al. Changes in central 5-HT(1A) receptor binding in mesial temporal epilepsy measured by positron emission tomography with [(11)C]WAY100635. Epilepsy Res. 2007;73:111–118
  71. Chugani DC, Chugani HT, Muzik O, et al. Imaging epileptogenic tubers in children with tuberous sclerosis complex using alpha-[11C]methyl-L-tryptophan positron emission tomography. Ann Neurol. 1998;44:858–866
  72. Fedi M, Reutens DC, Andermann F, et al. alpha-[11C]-Methyl-L-tryptophan PET identifies the epileptogenic tuber and correlates with interictal spike frequency. Epilepsy Res. 2003;52:203–213
  73. Kagawa K, Chugani DC, Asano E, et al. Epilepsy surgery outcome in children with tuberous sclerosis complex evaluated with alpha-[11C]methyl-L-tryptophan positron emission tomography (PET). J Child Neurol. 2005;20:429–438
  74. Marini C, Guerrini R. The role of the nicotinic acetylcholine receptors in sleep-related epilepsy. Biochem Pharmacol. 2007;74:1308–1314
  75. Picard F, Bruel D, Servent D, et al. Alteration of the in vivo nicotinic receptor density in ADNFLE patients: a PET study. Brain. 2006;129:2047–2060
  76. Iversen L. Cannabis and the brain. Brain. 2003;126:1252–1270
  77. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science. 2002;296:678–682
  78. Marsicano G, Goodenough S, Monory K, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003;302:84–88
  79. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol. 2006;105:1–25
  80. Wallace MJ, Wiley JL, Martin BR, et al. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol. 2001;428:51–57
  81. Wallace MJ, Martin BR, DeLorenzo RJ. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol. 2002;452:295–301
  82. Wallace MJ, Blair RE, Falenski KW, et al. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther. 2003;307:129–137
  83. Burns HD, Van Laere K, Sanabria-Bohorquez S, et al. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A. 2007;104:9800–9805
  84. Pitkänen A, Kharatishvili I, Karhunen H, et al. Epileptogenesis in experimental models. Epilepsia. 2007;48(suppl 2):13–20
  85. Kornblum HI, Araujo DM, Annala AJ, et al. In vivo imaging of neuronal activation and plasticity in the rat brain by high resolution positron emission tomography (microPET). Nat Biotechnol. 2000;18:655–660
  86. Mirrione MM, Schiffer WK, Siddiq M, et al. PET imaging of glucose metabolism in a mouse model of temporal lobe epilepsy. Synapse. 2006;59:119–121
  87. Jupp B, Williams J, Binns D, et al. Imaging small animal models of epileptogenesis. Neurology Asia. 2007;12(suppl 1):51–54
  88. Dedeurwaerdere S, Jupp B, O'Brien TJ. Positron emission tomography in basic epilepsy research: a view of the epileptic brain. Epilepsia. 2007;48(suppl 4):56–64
  89. Tipre DN, Zoghbi SS, Liow JS, et al. PET imaging of brain 5-HT1A receptors in rat in vivo with 18F-FCWAY and improvement by successful inhibition of radioligand defluorination with miconazole. J Nucl Med. 2006;47:345–353

PII: S0001-2998(08)00027-5

doi: 10.1053/j.semnuclmed.2008.02.004

Seminars in Nuclear Medicine
Volume 38, Issue 4 , Pages 227-239 , July 2008

Article Tools

* Image Usage & Resolution